Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, s...
Guardado en:
| Publicado en: | Antimicrob Agents Chemother |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society for Microbiology (ASM)
1997
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163683/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8980778/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.41.1.188 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|